바이러스 벡터 및 플라스미드 DNA 제조 시장 : 산업 규모, 점유율, 동향, 기회 및 예측, 제품 유형별, 용도별, 지역별, 경쟁별(2020-2030년)

Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product Type, By Application, By Region, & Competition, 2020-2030F

US $ 4,500 ￦ 6,529,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,979,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,607,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

바이러스 벡터 및 플라스미드 DNA 제조 세계 시장 규모는 2024년 68억 달러에 달할 것으로 예상되며, 예측 기간 동안 안정적인 성장세를 보이며 2030년까지 연평균 성장률(CAGR)은 10.85%를 보일 것으로 예측됩니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	68억 달러
시장 규모 : 2030년	126억 4,000만 달러
CAGR : 2025-2030년	10.85%
급성장 부문	플라스미드 DNA
최대 시장	북미

바이러스 벡터 및 플라스미드 DNA의 생산은 생명공학 및 바이오 제약 산업, 특히 유전자 치료, 백신 개발 및 유전공학에 적용하는 데 있어 기초가 되는 공정입니다. 이러한 공정에는 분자생물학 및 의학 연구에서 중요한 도구가 되는 바이러스 벡터와 플라스미드 DNA의 생산 및 정제가 포함됩니다.

시장 성장 촉진요인

바이오의약품 연구개발 투자 증가

주요 시장 이슈

비용 및 가격 압력

주요 시장 동향

세포-유전자치료 생태계 확장

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 바이러스 벡터 및 플라스미드 DNA 제조 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 제품 유형별(플라스미드 DNA, 바이러스 벡터, 비바이러스 벡터)
  • 용도별(암, 유전성 질환, 감염증, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 아시아태평양의 바이러스 벡터 및 플라스미드 DNA 제조 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제7장 유럽의 바이러스 벡터 및 플라스미드 DNA 제조 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제8장 북미의 바이러스 벡터 및 플라스미드 DNA 제조 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제9장 남미의 바이러스 벡터 및 플라스미드 DNA 제조 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 바이러스 벡터 및 플라스미드 DNA 제조 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제13장 세계의 바이러스 벡터 및 플라스미드 DNA 제조 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 PESTEL 분석

제16장 경쟁 구도

• Oxford Biomedica PLC
• Cognate BioServices Inc.
• Cell and Gene Therapy Catapult Ltd.
• FinVector Vision Therapies
• Fujifilm Holdings Corporation(Fujifilm Diosynth Biotechnologies)
• SIRION Biotech GmbH
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Uniqure NV
• Catalent Inc.

제17장 전략적 제안

제18장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

The global market for viral vector and plasmid DNA manufacturing was valued at USD 6.80 billion in 2024 and is projected to experience steady growth over the forecast period, with a compound annual growth rate (CAGR) of 10.85% through 2030.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 6.80 Billion
Market Size 2030	USD 12.64 Billion
CAGR 2025-2030	10.85%
Fastest Growing Segment	Plasmid DNA
Largest Market	North America

Viral vector and plasmid DNA production are foundational processes within the biotechnology and biopharmaceutical industries, especially for applications in gene therapy, vaccine development, and genetic engineering. These processes involve the production and purification of viral vectors and plasmid DNA, which serve as critical tools in molecular biology and medical research.

Key Market Drivers

Increased Investment in Biopharmaceutical R&D

The market is primarily driven by the surge in investment toward gene therapy research and development. Both viral vectors and plasmid DNA are integral to gene therapy products, which are gaining traction as promising treatments for rare and genetic diseases. These innovations have attracted significant funding from both public and private sectors.

As biopharmaceutical companies continue to expand their R&D budgets, there is a clear strategic emphasis on advanced therapies such as gene and cell therapies and DNA-based vaccines. In 2023, the top 20 global pharmaceutical firms-including Swiss leaders Novartis and Roche-collectively invested USD 145 billion in R&D, marking a 4.5% year-over-year increase. This sustained investment underscores a commitment to pipeline expansion and innovation-led growth, heavily reliant on viral vectors and plasmid DNA for therapeutic delivery.

Consequently, the rising number of research programs and preclinical studies is driving robust demand for high-quality viral vectors and plasmids. Manufacturers and suppliers are witnessing increased order volumes, more contract development opportunities, and the formation of long-term strategic partnerships.

Key Market Challenges

Cost and Pricing Pressures

The production of viral vectors and plasmid DNA is technically complex, involving multiple stages and specialized materials and equipment. As gene therapy moves from the research phase to commercial-scale manufacturing, companies face significant challenges in scaling up operations while maintaining stringent quality standards.

Achieving cost efficiencies without compromising product integrity is a persistent concern. In addition, compliance with strict regulatory frameworks necessitates investments in quality assurance, documentation, and control systems, adding to operational costs.

Establishing and maintaining GMP-compliant manufacturing facilities and cleanrooms requires substantial capital investment. Moreover, fluctuations in the prices of key raw materials-such as cell culture media, growth factors, and purification reagents-can further elevate production costs. Regulatory requirements for the safe disposal of biological and hazardous waste also contribute to financial pressure.

Key Market Trends

Expansion of the Cell and Gene Therapy Ecosystem

The development of the cell and gene therapy ecosystem is being propelled by collaborative efforts among academic institutions, research centers, and biopharmaceutical companies. These partnerships facilitate knowledge sharing, innovation, and resource pooling, accelerating the advancement of next-generation therapies.

Several countries have established dedicated research hubs and institutes focused on cell and gene therapy, providing infrastructure and a collaborative environment for scientific innovation. Notable biotech clusters-such as the Boston-Cambridge corridor in the United States and the Golden Triangle in the United Kingdom-serve as innovation centers, drawing investment and talent. Furthermore, increased funding and grant initiatives from both governmental and private sources continue to support the growth and maturation of the sector, reinforcing its long-term potential.

Key Market Players

• Oxford Biomedica PLC
• Cognate BioServices Inc.
• Cell and Gene Therapy Catapult Ltd.
• FinVector Vision Therapies
• Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
• SIRION Biotech GmbH
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Uniqure NV
• Catalent Inc.

Report Scope:

In this report, the Global Viral Vector and Plasmid DNA Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:

• Plasmid DNA
• Viral Vector
• Non-viral Vector

Viral Vector and Plasmid DNA Manufacturing Market, By Application:

• Cancer
• Genetic Disorder
• Infectious Disease
• Other

Viral Vector and Plasmid DNA Manufacturing Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Viral Vector and Plasmid DNA Manufacturing Market.

Available Customizations:

Global Viral Vector and Plasmid DNA Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Plasmid DNA, Viral Vector, Non-viral Vector)
  • 5.2.2. By Application (Cancer, Genetic Disorder, Infectious Disease, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Application
  • 6.3.2. India Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Australia Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Application
  • 6.3.4. Japan Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product Type
      • 6.3.4.2.2. By Application
  • 6.3.5. South Korea Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product Type
      • 6.3.5.2.2. By Application

7. Europe Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Application
  • 7.3.3. Spain Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Application
  • 7.3.5. United Kingdom Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Application

8. North America Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Application
  • 8.3.2. Mexico Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Canada Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Application

9. South America Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Viral Vector and Plasmid DNA Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Viral Vector and Plasmid DNA Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Oxford Biomedica PLC
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Cognate BioServices Inc.
• 16.3. Cell and Gene Therapy Catapult Ltd.
• 16.4. FinVector Vision Therapies
• 16.5. Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
• 16.6. SIRION Biotech GmbH
• 16.7. Merck KGaA
• 16.8. Thermo Fisher Scientific Inc.
• 16.9. Uniqure NV
• 16.10. Catalent Inc.

17. Strategic Recommendations

18. About Us & Disclaimer

관련자료